ADUS

Analyst Note: ADUS (Addus HomeCare Corporation)

Date: 2026-06-13 Current Price: $94.23

1. Structural Readiness

• State: Context-Only (Forming Coil)
• Aggressive/Pre-Breakout Entry: N/A (Forming coils are not standalone actionable entries; they require confirmation)
• Breakout Level: Not yet defined (Pending confirmation of the structural high that defines the coil top)
• Current Price: $94.23
• Extension: N/A (Price is within the forming range, not extended above a breakout level)
• ATR Context: Current ATR is 3.0% (Productive). This sits within the historical "productive" range, suggesting manageable volatility for position sizing, though it is below the 4–6% "sweet spot" often associated with high-momentum breakouts.

2. Thesis Layer

• Thesis Status: TACTICAL / Setup-Led
• Macro Thesis: None named at this date.
• Analysis: This is not a secular-theme driven name in the current context. The investment case must be judged strictly on the quality of the technical setup (the forming coil) and the underlying business fundamentals (revenue growth, margin stability, and execution). There is no external macro narrative to weight the conviction; the setup quality and business health are the sole drivers.

3. Business Overview

Addus HomeCare Corporation operates in the Healthcare sector, specifically within the Home and Community-Based Services (HCBS) industry. The company provides essential personal support services across the United States, structured into three primary segments: Personal Care, Hospice, and Home Health.

• Revenue Drivers: The Personal Care Services segment is the dominant engine, accounting for 77.3% of revenues as of Q1 2026. The Hospice segment contributed 18.1% of revenues in the same period.
• Growth & Acquisitions: The company is executing an active M&A strategy. As of the Q1 2026 earnings call (May 5, 2026), management confirmed the closing of the HomeCourt Home Care acquisition in Fort Wayne, Indiana, and the entry into a definitive agreement for an additional Indiana-based personal care operation. In 2025, the company completed four acquisitions (Gold Horses, Helping Hands, Great Lakes, and Jacksonville), which contributed $11.8 million in net service revenues for the full year.
• Payor Mix & Geography: The company serves approximately 107,000 discrete consumers (as of Dec 31, 2025) across 23 states and 262 offices. A significant portion of the consumer base is "dual eligible" (Medicare and Medicaid). The largest single payor is the Illinois Department on Aging, which accounted for 18.1% of net service revenues in 2025.
• Recent Catalysts: Management highlighted positive regulatory tailwinds, specifically a rate increase from the State of Illinois effective January 1, 2026, adding approximately $17.5 million in annualized revenues. Additionally, the New Mexico legislature included $10 million in increased funding for home and community-based services in the upcoming fiscal year.
• Operational Metrics: Hospice medium length of stay was 23 days in Q1 2026, up from 19 days in Q1 2025 but down from 25 days in Q4 2025, indicating stable utilization.
• Balance Sheet & Working Capital: As of March 31, 2026, the company held $103 million in cash. Accounts receivable decreased by $6.9 million sequentially to $144.8 million, with a notable improvement in collection days for the Illinois Department on Aging (down to 47 days from 55 days).

4. Archetype and Conviction

• Archetype: Quality Compounder
• Fit Rationale: The company demonstrates the characteristics of a compounder through consistent organic and inorganic growth, a dominant market position in a secularly growing sector (aging population), and improving operational efficiency (reduced DSOs). The "Quality" aspect is supported by the diverse client base (federal, state, managed care, commercial) and the "Compounder" aspect is evidenced by the aggressive acquisition strategy and the ability to integrate new revenue streams ($11.8M from 2025 acquisitions).
• Valuation Context: The financial spine indicates a forward consensus EPS of $6.99 for FY1 and $7.47 for FY2. At a current price of $94.23, the stock trades at approximately 13.5x forward FY1 EPS, suggesting a reasonable valuation for a healthcare compounder with double-digit growth expectations.
• Conviction Stack:
• Thesis Strength: Low (Tactical only, no macro thesis).
• Evidence Quality: High (Strong earnings transcript and SEC filing data confirming growth, cash position, and receivables management).
• Structural Quality: Moderate (Forming coil indicates accumulation, but lack of breakout confirmation limits immediate structural strength).
• Setup Readiness: Partial (Forming coil is a positive signal but requires a breakout to become actionable).
• Rerating Potential: Moderate (Dependent on successful integration of acquisitions and continued rate expansions in key states like Illinois and New Mexico).

5. Invalidations, Strengtheners, and Gaps

• Gaps in Evidence:
• Margin Data: The provided evidence lacks specific gross margin or operating margin figures for Q1 2026, making it difficult to assess the profitability of the recent acquisitions.
• Guidance: While management discussed rate increases, specific forward guidance for full-year 2026 revenue or EPS growth rates is not explicitly detailed in the provided transcript excerpts.
• Competitive Landscape: No data is provided regarding competitive pressures or market share changes in the 23 states of operation.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: Medium Key evidence: 1) Strong cash position of $103M and improving receivables (DSO down to 47 days for largest payor); 2) Active M&A strategy adding $11.8M in 2025 revenue with new Indiana acquisitions closed; 3) Positive regulatory tailwinds with $17.5M annualized revenue from Illinois rate hikes. Key risks: 1) High concentration risk with Illinois Department on Aging representing 18.1% of revenue; 2) Integration risk of multiple recent acquisitions; 3) Dependence on government payor rate cycles. Sizing hint: Position size should reflect the "Forming" status; allocate based on the potential for a breakout rather than current momentum. Expected path: Management expects continued growth from the aging population and successful integration of acquired entities, with rate expansions in key states driving top-line growth. Expected horizon: 3 to 6 months for the forming coil to resolve into a confirmed breakout or invalidation.